Alzheimer's disease: strategies for disease modification

被引：888

作者：

Citron, Martin ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 05期

关键词：

AMYLOID-BETA-PEPTIDE; POSITRON-EMISSION-TOMOGRAPHY; GAMMA-SECRETASE INHIBITOR; A-BETA; APOLIPOPROTEIN-E; MOUSE MODEL; MEMORY DEFICITS; ANIMAL-MODEL; DOUBLE-BLIND; FOLLOW-UP;

D O I：

10.1038/nrd2896

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Alzheimer's disease is the largest unmet medical need in neurology. Current drugs improve symptoms, but do not have profound disease-modifying effects. However, in recent years, several approaches aimed at inhibiting disease progression have advanced to clinical trials. Among these, strategies targeting the production and clearance of the amyloid-beta peptide - a cardinal feature of Alzheimer's disease that is thought to be important in disease pathogenesis - are the most advanced. Approaches aimed at modulating the abnormal aggregation of tau filaments (another key feature of the disease), and those targeting metabolic dysfunction, are also being evaluated in the clinic. This article discusses recent progress with each of these strategies, with a focus on anti-amyloid strategies, highlighting the lessons learned and the challenges that remain.

引用

页码：387 / 398

页数：12

共 105 条

[51] Serial PIB and MRI in normal, mild cognitive impairment and Alzheimers disease: implications for sequence of pathological events in Alzheimers disease [J].

Jack, Clifford R., Jr. ;

Lowe, Val J. ;

Weigand, Stephen D. ;

Wiste, Heather J. ;

Senjem, Matthew L. ;

Knopman, David S. ;

Shiung, Maria M. ;

Gunter, Jeffrey L. ;

Boeve, Bradley F. ;

Kemp, Bradley J. ;

Weiner, Michael ;

Petersen, Ronald C. .

BRAIN, 2009, 132 :1355-1365

[52]

Jacobsen S., 2007, NEURODEGEN DIS S1, V4, P22

[53] Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease [J].

Janus, C ;

Pearson, J ;

McLaurin, J ;

Mathews, PM ;

Jiang, Y ;

Schmidt, SD ;

Chishti, MA ;

Horne, P ;

Heslin, D ;

French, J ;

Mount, HTJ ;

Nixon, RA ;

Mercken, M ;

Bergeron, C ;

Fraser, PE ;

St George-Hyslop, P ;

Westaway, D .

NATURE, 2000, 408 (6815) :979-982

[54] THE CARBOXY TERMINUS OF THE BETA-AMYLOID PROTEIN IS CRITICAL FOR THE SEEDING OF AMYLOID FORMATION - IMPLICATIONS FOR THE PATHOGENESIS OF ALZHEIMERS-DISEASE [J].

JARRETT, JT ;

BERGER, EP ;

LANSBURY, PT .

BIOCHEMISTRY, 1993, 32 (18) :4693-4697

[55] Therapeutic potential of statins in Alzheimer's disease [J].

Kandiah, Nagaendran ;

Feldman, Howard H. .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 283 (1-2) :230-234

[56] Substrate-targeting γ-secretase modulators [J].

Kukar, Thomas L. ;

Ladd, Thomas B. ;

Bann, Maralyssa A. ;

Fraering, Patrick C. ;

Narlawar, Rajeshwar ;

Maharvi, Ghulam M. ;

Healy, Brent ;

Chapman, Robert ;

Welzel, Alfred T. ;

Price, Robert W. ;

Moore, Brenda ;

Rangachari, Vijayaraghavan ;

Cusack, Bernadette ;

Eriksen, Jason ;

Jansen-West, Karen ;

Verbeeck, Christophe ;

Yager, Debra ;

Eckman, Christopher ;

Ye, Wenjuan ;

Sagi, Sarah ;

Cottrell, Barbara A. ;

Torpey, Justin ;

Rosenberry, Terrone L. ;

Fauq, Abdul ;

Wolfe, Michael S. ;

Schmidt, Boris ;

Walsh, Dominic M. ;

Koo, Edward H. ;

Golde, Todd E. .

NATURE, 2008, 453 (7197) :925-U62

[57] BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions [J].

Laird, FM ;

Cai, HB ;

Savonenko, AV ;

Farah, MH ;

He, KW ;

Melnikova, T ;

Wen, HJ ;

Chiang, HC ;

Xu, GL ;

Koliatsos, VE ;

Borchelt, DR ;

Price, DL ;

Lee, HK ;

Wong, PC .

JOURNAL OF NEUROSCIENCE, 2005, 25 (50) :11693-11709

[58] Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease [J].

Lambert, Jean-Charles ;

Heath, Simon ;

Even, Gael ;

Campion, Dominique ;

Sleegers, Kristel ;

Hiltunen, Mikko ;

Combarros, Onofre ;

Zelenika, Diana ;

Bullido, Maria J. ;

Tavernier, Beatrice ;

Letenneur, Luc ;

Bettens, Karolien ;

Berr, Claudine ;

Pasquier, Florence ;

Fievet, Nathalie ;

Barberger-Gateau, Pascale ;

Engelborghs, Sebastiaan ;

De Deyn, Peter ;

Mateo, Ignacio ;

Franck, Ana ;

Helisalmi, Seppo ;

Porcellini, Elisa ;

Hanon, Olivier ;

de Pancorbo, Marian M. ;

Lendon, Corinne ;

Dufouil, Carole ;

Jaillard, Celine ;

Leveillard, Thierry ;

Alvarez, Victoria ;

Bosco, Paolo ;

Mancuso, Michelangelo ;

Panza, Francesco ;

Nacmias, Benedetta ;

Bossu, Paola ;

Piccardi, Paola ;

Annoni, Giorgio ;

Seripa, Davide ;

Galimberti, Daniela ;

Hannequin, Didier ;

Licastro, Federico ;

Soininen, Hilkka ;

Ritchie, Karen ;

Blanche, Helene ;

Dartigues, Jean-Francois ;

Tzourio, Christophe ;

Gut, Ivo ;

Van Broeckhoven, Christine ;

Alperovitch, Annick ;

Lathrop, Mark ;

Amouyel, Philippe .

NATURE GENETICS, 2009, 41 (10) :1094-U68

[59] Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial (vol 7, pg 779, 2008) [J].

Lannfelt, L. ;

Blennow, K. ;

Zetterberg, H. .

LANCET NEUROLOGY, 2009, 8 (11) :981-981

[60]

Lee VMY, 2006, J ALZHEIMERS DIS, V9, P257

← 1 2 3 4 5 6 7 8 9 10 →